Drawing for MH MOLECULAR HEALTH

USPTO serial 87048078

MH MOLECULAR HEALTH

Reviewed by CopyMark Law Group

Reg. 6420058Status 700Renewal
Filing date
Status date
Registration date
Jul 13, 2021
Examiner
HISER, CHARLES
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with MH MOLECULAR HEALTH?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $2,144*

Plus Government fees of $1,950

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Peter T. Wakiyama

Peter T. Wakiyama Troutman Pepper Hamilton Sanders LLP3000 Two Logan SquarePhiladelphia, PA 19103UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
009Downloadable computer databases containing information in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals, life sciences and biotechnology; downloadable computer databases containing medical and health information or records about or relating to humans; downloadable computer software for accessing, organizing, indexing, ranking, integrating, linking, referencing, synthesizing, interpreting and analyzing information from databases in the fields of medicine, health care, genomics, pharmaceuticals, life sciences and biotechnology and databases containing medical and health information or records about or relating to humans, including biomedical databases containing information about clinical, genomic, molecular, scientific and patient specific data, in particular information that clinicians and researchers enable to interpret complex molecular and genomic patient information; downloadable computer databases in the field of biomedical information, in particular links to external reference databases, in particular for the alignment and integration of biomedical information; downloadable computer software and algorithms for storing and sorting biomedical information, in particular links to external reference databases, in particular for the alignment and integration of biomedical information, updating and expanding global reference data sources across diverse medical disciplines and for allowing the immediate access to biomedical information; downloadable computer databases containing biomedical information in form of human genome sequences, information about indication and classifications of diseases, biomarkers, information about the molecular mechanism of action of drugs, their targets, metabolizing enzymes, information about scientific publications from diverse areas of biomedicine drug-to-drug interactions and the status of drug development; downloadable computer software and algorithms for authorizing or providing access to biomedical databases, in particular application software, interface software, software drives, data communication software, interactive computer software; downloadable computer software and software components for serving domain-specific user demands; downloadable mobile applications for mobile devices, such as smart phones and tablet computers, for accessing, organizing, synthesizing, indexing, ranking, integrating, linking, referencing, interpreting and analyzing information from databases in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals, life sciences and biotechnology and databases containing medical and health information or records about or relating to humansACTIVENov 1, 2019
035Business consulting and research services for employers in the field of employee benefits in the nature of offering medical and health care plans to employees and their family members and domestic partners for medical and health care diagnostic and treatment support programsACTIVENov 1, 2019
036Financial administration of programs and services for payment and reimbursement of employee benefits in the nature of medical and health care diagnostic and treatment support programs, for employees and their family members and domestic partnersACTIVENov 1, 2019
038Providing access to searchable databases containing medical, pharmaceutical, biological, clinical and genomic information and medical and health information or records, molecular test results and patient specific data about or relating to humans for scientific research purposes; providing access to non-downloadable computer software and algorithms for use by physicians, clinicians and other healthcare professionals, laboratory personnel, consultants, scientists and other researchers for medical diagnostic and treatment and drug safety research and drug or pharmaceuticals or other treatment discovery, research and development; providing access to non-downloadable software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment research and drug or pharmaceuticals or other treatment discovery, research and development purposes; providing access to non-downloadable computer software and algorithms for use by physicians, clinicians and other healthcare professionals, laboratory personnel, consultants, scientists and other researchers for medical diagnostic and treatment purposes; providing access to software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; providing access to databases containing medical, pharmaceutical, biological, clinical, molecular, sequencing and genomic information, disease information, biomarker information and medical or health information or records about or relating to humans and patient specific data, molecular test results, and scientific research for medical diagnostic and treatment purposesACTIVENov 1, 2019
042Scientific consulting and research services in the fields of health care, medicine, life sciences, biotechnology, pharmaceuticals, bioinformatics, genomics and pharmaceuticals and pharmaceutical safety for scientific research purposes; Scientific consulting and research services for the retrieval, integration, correlation, analysis and interpretation of genomic data, sequencing data, and molecular data, disease, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment research and drug or pharmaceuticals or other treatment discovery, research and development purposes; designing and developing and providing temporary use of online searchable databases containing medical, pharmaceutical, biological, clinical and genomic information and medical and health information or records, molecular test results and patient specific data about or relating to humans for scientific research purposes; designing and developing and providing temporary use of non-downloadable computer software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data and information on diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, patient specific data, molecular test results, data from clinical studies, and scientific research for use by physicians, clinicians and other healthcare professionals, laboratory personnel, consultants, scientists and other researchers for medical diagnostic and treatment and drug safety research and drug or pharmaceuticals or other treatment discovery, research and development; designing and developing and providing temporary use of non-downloadable software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment research and drug or pharmaceuticals or other treatment discovery, research and development purposes; software as a Service (SaaS) used in research and consulting for enabling the retrieval, integration, correlation, analysis and interpretation of genomic data, sequencing data and molecular data, disease information, biomarker information, drug protocols, drug interactions, clinical profiles, and patient specific data, molecular test results, data from clinical studies, and scientific research and health and medical information, records or data for medical, diagnostic and treatment and drug safety research and drug or pharmaceuticals or other treatment discovery, research and development purposes; provision of non-downloadable mobile applications for mobile devices, such as smart phones and tablets, and non-downloadable web applications accessible through the Internet for accessing databases in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals and pharmaceutical safety, life sciences and biotechnology; data collection services for scientific research purposes in the fields of genomics, health care, pharmaceuticals, life sciences, bioinformatics, biotechnology and medicine; scientific research services for the retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; providing temporary use of non-downloadable computer software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data and information on diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, patient specific data, molecular test results, data from clinical studies, and scientific research for use by physicians, clinicians and other healthcare professionals, laboratory personnel, consultants, scientists and other researchers for medical diagnostic and treatment purposes; providing temporary use of non-downloadable software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic data, sequencing data and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; providing information in the fields of life sciences, biotechnology, bioinformaticsACTIVENov 1, 2019
044Medical consulting services for the retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; providing online databases containing medical, pharmaceutical, biological, clinical, molecular, sequencing and genomic information, disease information, biomarker information and medical or health information or records about or relating to humans and patient specific data, molecular test results, and scientific research for medical diagnostic and treatment purposes; medical consulting services in the fields of health, medical care, biotechnology, bioinformatics, life sciences, pharmaceuticals and medicine; providing information in the fields of health, healthcare, pharmaceuticals and pharmaceutical safety, genetic testing for medical purposes; medical consulting services with respect to the treatment and diagnosis of individuals; providing pharmaceutical information, including information about drug safety and drug compatibility in relation to therapy and the treatment of individuals; medical consulting services in the fields of diagnostics and patient treatment and treatment protocolsACTIVENov 1, 2019

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 13, 2026REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jul 13, 2021R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 9, 2021SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Jun 8, 2021CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
May 25, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 25, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 25, 2021ALIEASSIGNED TO LIE—
Feb 22, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 21, 2020GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 21, 2020GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 21, 2020CNRTSU - NON-FINAL ACTION - WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 31, 2020SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Jul 10, 2020IUAFUSE AMENDMENT FILED—
Jul 10, 2020EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Jan 15, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 14, 2020EX5GSOU EXTENSION 5 GRANTED—
Jan 9, 2020EXT5SOU EXTENSION 5 FILED—
Jan 9, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 13, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 11, 2019EX4GSOU EXTENSION 4 GRANTED—
Jul 11, 2019EXT4SOU EXTENSION 4 FILED—
Jul 11, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 15, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 11, 2019TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 11, 2019EX3GSOU EXTENSION 3 GRANTED—
Jan 11, 2019EXT3SOU EXTENSION 3 FILED—
Jan 11, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 13, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 11, 2018EX2GSOU EXTENSION 2 GRANTED—
Jul 11, 2018EXT2SOU EXTENSION 2 FILED—
Jul 11, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 11, 2018TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 21, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 20, 2018EX1GSOU EXTENSION 1 GRANTED—
Feb 20, 2018AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Feb 5, 2018NREVNOTICE OF REVIVAL - E-MAILED—
Feb 5, 2018TPEXSOU EXTENSION RECEIVED WITH TEAS PETITION—
Feb 5, 2018PETGPETITION TO REVIVE-GRANTED—
Feb 5, 2018PROATEAS PETITION TO REVIVE RECEIVED—
Jan 11, 2018EXT1SOU EXTENSION 1 FILED—
Jul 11, 2017NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 16, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 16, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 26, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 6, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 5, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 5, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 5, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 27, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 27, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 27, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 15, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 15, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 15, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 16, 2016GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 16, 2016GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 16, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 8, 2016DOCKASSIGNED TO EXAMINER—
Jun 2, 2016MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Jun 1, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 27, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance